Zelira Therapeutics Ltd has announced the US launch of the Zelira Dermatology Business’ first product line, RAF FIVE, through its dermatology subsidiary Ilera Derm LLC (Zelira Dermatology).
 
The five-product RAF FIVE line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads.
 
The products include known skin-boosting ingredients hyaluronic acid, niacinamide, glycerin, thiotaine (derived from mushrooms), and peptides. The RAF FIVE line is Zelira’s first step into the acne medication market valued at more than $11 billion worldwide.
 
Special Complex Zylorma
 
Available now in the United States, RAF FIVE features Zylorma, a patent-pending acne fighting complex developed by Zelira and US board-certified cosmetic dermatologist Dr. Karyn Grossman.
 
Zylorma uses a proprietary formulation with CBD, salicylic acid and additional botanical compounds to fight bacteria and clogged pores associated with acne, and balance sebum production to help eliminate and prevent acne breakouts. RAF FIVE uses pharmaceutical-grade CBD isolate derived from hemp and is THC-free.
 
Zelira Therapeutics CEO and managing director, Dr. Oludare Odumosu, commented, “We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the $11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs. Zelira is staking a claim in the cannabinoid-based, over-the-counter skincare product market with our differentiated dermatology.”
 
Dr. Karyn Grossman commented, “I am thrilled to be a part of the new Zelira Dermatology and to have teamed up with Zelira to create Zylorma and the RAF FIVE skin care line. Zelira is already known as a leader in cannabinoid research and development for the medical cannabis market, so when they offered me the opportunity to use my medical expertise alongside their ground-breaking scientific formulations to create a truly new and unique solution for acne, I couldn’t pass it up.”
 
Study Results
 
Zelira also conducted a rigorous industry standard consumer use study for the RAF FIVE franchise that showed improvement in all of the participants during the 28 day study. Results showed significant improvement as early as seven days for some of the participants.
 
Zelira’s Dermatology subsidiary is currently developing several other topical products, anticipated to be launched in 2022 including anti-aging, sexual health/intimacy, and specific skin conditions such as psoriasis.